Early-Stage trial for Friedreich's ataxia drug in kids halted
NCT ID NCT06681766
First seen Jan 28, 2026 · Last updated May 14, 2026 · Updated 15 times
Summary
This early-stage study aimed to check the safety of a drug called nomlabofusp in 18 children and teenagers (ages 2 to 17) with Friedreich's ataxia, a rare genetic disease that affects movement and heart function. The drug was given as a shot under the skin. The study was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FRIEDREICH ATAXIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Uncommon Cures
Chevy Chase, Maryland, 20815, United States
Conditions
Explore the condition pages connected to this study.